iTeos Therapeutics (ITOS) to Join S&P SmallCap 600
Get Alerts ITOS Hot Sheet
Join SI Premium – FREE
iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, January 5. S&P 500 constituent Centene Corp. (NYSE: CNC) is acquiring Magellan Health in a deal expected to be completed soon pending final conditions.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date | Index Name | Action | Company Name | Ticker | GICS Sector |
January 5, 2022 | S&P SmallCap 600 | Addition | iTeos Therapeutics | ITOS | Health Care |
S&P SmallCap 600 | Deletion | Magellan Health | MGLN | Health Care |
For more information about S&P Dow Jones Indices, please visit www.spdji.com
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Reddit (RDDT) added to S&P 500
- Globalstar confirms launch of 8 HIBLEO-4 replacement satellites
- HII completes acceptance sea trials for carrier John F. Kennedy
Create E-mail Alert Related Categories
Corporate News, Index ChangesRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share